Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension phase II study of imatinib in chronic myeloid leukemia patients refractory or intolerant to interferon-alpha
2005-001382-33Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Overall survival. Started Jun 2005; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2005-001382-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001382-33.